2-哌嗪-1-基-1-哌啶-1-基乙酮 | 70558-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-哌嗪-1-基-1-哌啶-1-基乙酮
• 英文名称: 2-(piperazin-1-yl)-1-(piperidin-1-yl)ethan-1-one
• 英文别名: 1-(2-oxo-2-piperidin-1-ylethyl)piperazine；2-piperazin-1-yl-1-piperidin-1-ylethanone
• CAS: 70558-13-3
• 化学式: C₁₁H₂₁N₃O
• mdl: MFCD01075233
• 分子量: 211.307
• InChiKey: PCHXUJGLAFXWIW-UHFFFAOYSA-N

物化性质

• 沸点：
  370.8±27.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,4-二氯-6-甲基嘧啶 、 2-哌嗪-1-基-1-哌啶-1-基乙酮 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Development of 2,4-diaminopyrimidine derivatives as novel SNSR4 antagonists

  摘要：

  2,4-Diaminopyrimidines derivatives were developed as a novel class of SNSR4 antagonists. Structure activity relationship of the diamino pyrimidine core was explored and a tool compound suitable for target validation was identified. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.138
• 作为产物：
  描述：

  N-Boc-哌嗪 、 氯乙酰氯 、 哌啶 生成 2-哌嗪-1-基-1-哌啶-1-基乙酮
  参考文献：
  名称：

  Cis-imidazolines

  摘要：

  本文介绍了公式或其药学上可接受的盐，其中Y1、Y2、X1、X2、X3和R的描述如本申请所述。据信这些化合物能够抑制MDM2-p53的相互作用，因此这些化合物将具有抗高增殖细胞活性。

  公开号：

  US20060211693A1

文献信息

• Catalytic hydrogenation of functionalized amides under basic and neutral conditions
  作者：Jeremy M. John、Rasu Loorthuraja、Evan Antoniuk、Steven H. Bergens

  DOI：10.1039/c4cy01227e

  日期：——

  A new, base-free high turnover number (TON) catalyst for hydrogenation of simple and functionalized amides is prepared by reacting [Ru(η3-C3H5)(Ph2P(CH2)2NH2)2]BF4 and BH4− under hydrogen. The hydrogenation proceeds with C–N cleavage to form the corresponding amine and alcohol. The base-free and base-promoted hydrogenations tolerate alcohols, amines, aromatic bromides, chlorides and fluorides, ethers

  对于简单的氢化和官能化的酰胺一种新的，无碱基的高转换数（TON）催化剂通过的[Ru（η反应制备3 -C 3 H ^ 5）（PH 2 P（CH 2）2 NH 2）2 ] BF 4和BH 4 -在氢气下。氢化过程通过C–N裂解形成相应的胺和醇。无碱和碱促进的氢化反应可耐受醇，胺，芳族溴化物，氯化物和氟化物，醚，某些烯烃和N杂环。该反应用于使某些乙酰基酰胺中的胺基脱保护，以形成例如含有芳基溴的N-杂环胺。无碱体系还选择性地氢化N-酰基氧杂唑烷酮，而不在α位上发生差向异构化，并还原β-内酰胺以形成相应的氨基醇。
• [EN] 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE 6-PHÉNYL OU 6-(PYRIDIN-3-YL)INDAZOLE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2015112445A1

  公开（公告）日：2015-07-30

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书所述，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制造这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use
  申请人：ABBVIE INC.

  公开号：US20160376240A1

  公开（公告）日：2016-12-29

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书中所定义，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制备这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• BMP-SIGNAL-INHIBITING COMPOUND
  申请人：RIKEN

  公开号：US20190337926A1

  公开（公告）日：2019-11-07

  The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

  本发明涉及一种新颖且优秀的小分子化合物，可以特异性拮抗BMP信号通路，这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病理症状，包括炎症、心血管疾病、造血系统疾病、癌症、骨发育不良等，特别是纤维性骨化进行性疾病。本发明涉及提供一种用于特异性拮抗BMP信号通路并作用于BMP信号通路的药物和药理剂，用于预防和治疗或实验应用，因为这些化合物有助于调节细胞分化和/或细胞增殖。
• Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
  申请人：Chamoin Sylvie

  公开号：US20100075966A1

  公开（公告）日：2010-03-25

  The invention relates to dihydroimidazoles of formula rac-(I), wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative diseases or for the manufacture of pharmaceutical formulations useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide, a pharmaceutical formulation e.g. useful in the treatment of proliferative diseases that respond to modulation of the interaction of the MDM2 protein with a p53-like peptide comprising said compound, methods of treatment comprising administration of said compounds to a warm-blooded animal, and/or processes for the manufacture of said compounds.

  该发明涉及式rac-(I)的二氢咪唑，其中基团和符号如本文所定义；它们作为MDM2蛋白与类p53肽的相互作用抑制剂的用途，包括所述化合物的新药物配方，所述化合物用于治疗温血动物，特别是人类，它们用于治疗增殖性疾病或用于制造对MDM2蛋白与类p53肽相互作用调节有响应的药物配方，例如用于治疗对MDM2蛋白与类p53肽相互作用调节有响应的增殖性疾病的药物配方，包括所述化合物，包括所述化合物的治疗方法，包括将所述化合物用于温血动物的给药，和/或所述化合物的制造方法。